Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer

• DOI: 10.4143/crt.2011.43.2.89
• Publication Date: 2011-07-15T08:43:22Z
• Authors: Su Jin Lee; Silvia Park; Hee Kyung Ahn; Jun Ho Yi; Eun Yoon Cho; Jong Mu Sun; Jeong Eon Lee; Seok Jin Nam; Jung-Hyun Yang; Yeon Hee Park; Jin Seok Ahn; Young-Hyuck Im
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Original Article; 3. Good health

The aim of the current study was to determine incidence, clinical presentation, and treatment outcomes "bone-only metastases" in patients with breast cancer analyze impact hormone receptor (HR) human epidermal growth factor 2 (HER2) status on prognosis.Between 1994 2007, 968 metastatic who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed distant metastases. Of 968, 146 (15%) had bone-only metastases during a median follow-up period 75 months. Among metastases, 122 (84%) were after curative surgery 24 (26%) initially cases.The time from primary 37 months (95% confidence interval [CI], 27 46 months). Bone-only more common HR-positive group than other subtypes (85% for HR+; 8.2% HER2+; 6.8% triple negative. all patients, (51%) treated therapy. post-relapse progression-free survival 15 CI, 13 17 overall much longer HR+ HER2+ negative marginal statistical significance (65 vs. 40 months, p=0.077).Breast excellent outcomes. Further is now warranted reveal underlying biology that regulates behavior this indolent tumor, as it should identify 'favorable tumor characteristics' addition preferential site.'